Incidence of young-onset dementia in Italy: The Brescia register study.

IF 4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI:10.1002/dad2.12544

Barbara Borroni, Ilenia Libri, Matteo Rota, Giuliano Binetti, Luisa Benussi, Roberta Ghidoni, Maria Sofia Cotelli, Silvia Fostinelli, Fabio Guerini, Stefano Boffelli, Eugenio Magni, Marta Pengo, Michele Gennuso, Marta Bianchi, Beatrice Cossu, Vincenzo Palomba, Andrea Crucitti, Angelo Bianchetti, Giancarlo Logroscino, Alessandro Padovani

{"title":"Incidence of young-onset dementia in Italy: The Brescia register study.","authors":"Barbara Borroni, Ilenia Libri, Matteo Rota, Giuliano Binetti, Luisa Benussi, Roberta Ghidoni, Maria Sofia Cotelli, Silvia Fostinelli, Fabio Guerini, Stefano Boffelli, Eugenio Magni, Marta Pengo, Michele Gennuso, Marta Bianchi, Beatrice Cossu, Vincenzo Palomba, Andrea Crucitti, Angelo Bianchetti, Giancarlo Logroscino, Alessandro Padovani","doi":"10.1002/dad2.12544","DOIUrl":null,"url":null,"abstract":"Introduction: The goal of the present work was to assess the incidence of dementia with onset before the age of 65 years (i.e., young-onset dementia [YOD]) and define the frequencies of young-onset Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), and dementia with Lewy bodies (DLB) in the general population.Methods: The study was conducted from January 1, 2019 to December 31, 2019 in Brescia province (population: 1,268,455). During the study period, all new YOD cases (incident YOD) were counted, and all patients' records reviewed. The incidence was standardized to the Italian general population in 2019.Results: A total of 29 YOD patients were diagnosed. The age-sex standardized incidence rate was 4.58 (95% confidence interval, 3.07-6.58) per 100,000 person-years. No difference in incidence rate between YOD due to AD or FTLD (P = 0.83) and between sexes (P = 0.81) was observed. YOD incidence increased with age, reaching its peak after 60 years.Discussion: Presenting neurodegenerative YOD phenotypes encompasses both AD and FTLD. Improved knowledge on YOD epidemiology is essential to adequately plan and organize health services.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 1","pages":"e12544"},"PeriodicalIF":4.0000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904882/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.12544","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The goal of the present work was to assess the incidence of dementia with onset before the age of 65 years (i.e., young-onset dementia [YOD]) and define the frequencies of young-onset Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), and dementia with Lewy bodies (DLB) in the general population.

Methods: The study was conducted from January 1, 2019 to December 31, 2019 in Brescia province (population: 1,268,455). During the study period, all new YOD cases (incident YOD) were counted, and all patients' records reviewed. The incidence was standardized to the Italian general population in 2019.

Results: A total of 29 YOD patients were diagnosed. The age-sex standardized incidence rate was 4.58 (95% confidence interval, 3.07-6.58) per 100,000 person-years. No difference in incidence rate between YOD due to AD or FTLD (P = 0.83) and between sexes (P = 0.81) was observed. YOD incidence increased with age, reaching its peak after 60 years.

Discussion: Presenting neurodegenerative YOD phenotypes encompasses both AD and FTLD. Improved knowledge on YOD epidemiology is essential to adequately plan and organize health services.

查看原文本刊更多论文

意大利青年痴呆症发病率：布雷西亚登记研究

导言：本研究旨在评估65岁前发病的痴呆症（即年轻发病痴呆症[YOD]）的发病率，并确定普通人群中年轻发病阿尔茨海默病（AD）、额颞叶变性（FTLD）和路易体痴呆（DLB）的发病频率：研究于 2019 年 1 月 1 日至 2019 年 12 月 31 日在布雷西亚省（人口：1,268,455）进行。在研究期间，对所有新发 YOD 病例（YOD 事件）进行了统计，并审查了所有患者的病历。发病率以2019年意大利总人口为标准：结果：共有 29 名 YOD 患者被确诊。年龄-性别标准化发病率为每 10 万人年 4.58 例（95% 置信区间，3.07-6.58）。AD或FTLD导致的YOD发病率无差异（P = 0.83），性别间也无差异（P = 0.81）。YOD发病率随年龄增长而增加，60岁后达到高峰：讨论：神经退行性YOD表型包括AD和FTLD。增进对 YOD 流行病学的了解对于充分规划和组织医疗服务至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.